| The insulin/IGF system in colorectal cancer development and resistance to therapy PG Vigneri, E Tirrò, MS Pennisi, M Massimino, S Stella, C Romano, ... Frontiers in oncology 5, 230, 2015 | 192 | 2015 |
| AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? F Martorana, G Motta, G Pavone, L Motta, S Stella, SR Vitale, L Manzella, ... Frontiers in Pharmacology 12, 546, 2021 | 151 | 2021 |
| Molecular alterations in thyroid cancer: From bench to clinical practice E Tirrò, F Martorana, C Romano, SR Vitale, G Motta, S Di Gregorio, ... Genes 10 (9), 709, 2019 | 94 | 2019 |
| Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study S Soverini, L Bavaro, C De Benedittis, M Martelli, A Iurlo, N Orofino, ... Blood 135 (8), 534-541, 2020 | 85 | 2020 |
| New insights in thyroid cancer and p53 family proteins L Manzella, S Stella, MS Pennisi, E Tirrò, M Massimino, C Romano, ... International journal of molecular sciences 18 (6), 1325, 2017 | 85 | 2017 |
| Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes F Stagno, S Stella, A Spitaleri, MS Pennisi, F Di Raimondo, P Vigneri Expert review of anticancer therapy 16 (3), 273-278, 2016 | 71 | 2016 |
| Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia M Massimino, S Stella, E Tirrò, C Romano, MS Pennisi, A Puma, ... Molecular cancer 17 (1), 1-15, 2018 | 68 | 2018 |
| Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs S Stella, E Tirro, E Conte, F Stagno, F Di Raimondo, L Manzella, P Vigneri Molecular cancer therapeutics 12 (6), 1085-1098, 2013 | 61 | 2013 |
| Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors F Stagno, P Vigneri, VD Fabro, S Stella, A Cupri, M Massimino, C Consoli, ... Acta Oncologica 49 (4), 506-508, 2010 | 56 | 2010 |
| The role of new technologies in myeloproliferative neoplasms GA Palumbo, S Stella, MS Pennisi, C Pirosa, E Fermo, S Fabris, ... Frontiers in oncology 9, 321, 2019 | 50 | 2019 |
| Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment L Manzella, M Massimino, S Stella, E Tirrò, MS Pennisi, F Martorana, ... International journal of molecular sciences 20 (13), 3258, 2019 | 45 | 2019 |
| High BCR–ABL/GUSIS levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib P Vigneri, F Stagno, S Stella, A Cupri, S Forte, M Massimino, A Antolino, ... Clinical Cancer Research 23 (23), 7189-7198, 2017 | 38 | 2017 |
| IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation M Massimino, ML Consoli, M Mesuraca, F Stagno, E Tirrò, S Stella, ... Carcinogenesis 35 (5), 1132-1143, 2014 | 34 | 2014 |
| ABL1-directed inhibitors for CML: efficacy, resistance and future perspectives M Massimino, S Stella, E Tirro, MS Pennisi, SR Vitale, A Puma, ... Anticancer research 40 (5), 2457-2465, 2020 | 33 | 2020 |
| Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma E Tirrò, M Massimino, C Romano, F Martorana, MS Pennisi, S Stella, ... Frontiers in Oncology 10, 2020 | 33 | 2020 |
| Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay B Tomasello, S Grasso, G Malfa, S Stella, M Favetta, M Renis Journal of medicinal food 15 (5), 441-447, 2012 | 33 | 2012 |
| Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer C Romano, F Martorana, MS Pennisi, S Stella, M Massimino, E Tirrò, ... International Journal of Molecular Sciences 22 (14), 7707, 2021 | 28 | 2021 |
| Chk1 inhibition restores inotuzumab ozogamicin citotoxicity in cd22-positive cells expressing mutant p53 E Tirrò, M Massimino, C Romano, MS Pennisi, S Stella, SR Vitale, ... Frontiers in oncology 9, 57, 2019 | 27 | 2019 |
| Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells M Massimino, E Tirro, S Stella, F Frasca, V Vella, L Sciacca, MS Pennisi, ... Anticancer research 38 (12), 6653-6662, 2018 | 27 | 2018 |
| Biomarkers and prognostic factors for malignant pleural mesothelioma P Vigneri, F Martorana, L Manzella, S Stella Future oncology 11 (24s), 29-33, 2015 | 25 | 2015 |
